Lantern Pharma(LTRN)
$0.28-0.05 (-13.98%)
LTRN
Lantern Pharma financials statements
$0.28
At close:-0.05 (-13.98%)
Want to see LTRN full AI Analyst Report?
Lantern Pharma (LTRN) Ratios
343 Followers
Lantern Pharma Ratios
LTRN's free cash flow for Q3 2026 was $-3.34M. For the 2026 fiscal year, LTRN's free cash flow was increased by $3.00 and operating cash flow was $-3.34M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.40 | 5.83 | 16.18 | 20.99 | 31.26 |
| Quick Ratio | 2.40 | 5.83 | 16.18 | 20.99 | 31.26 |
| Cash Ratio | 0.98 | 1.73 | 8.19 | 13.29 | 22.15 |
| Solvency Ratio | -3.80 | -4.74 | -5.76 | -5.09 | -5.19 |
| Operating Cash Flow Ratio | -3.48 | -4.11 | -5.36 | -4.56 | -4.55 |
| Short-Term Operating Cash Flow Coverage | -0.20 | 0.00 | 0.00 | 0.00 | -69.65 |
| Net Current Asset Value | $ 6.30M | $ 20.86M | $ 40.60M | $ 55.92M | $ 70.34M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 7.12 | 0.01 | 0.01 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 12.02 | 0.01 | 0.01 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.92 | 0.01 | 0.01 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.69 | 1.21 | 1.07 | 1.05 | 1.03 |
| Debt Service Coverage Ratio | -0.22 | 0.00 | 0.00 | -70.58 | -82.76 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -70.63 | 0.00 |
| Debt to Market Cap | 2.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 7.21 | 0.02 | 0.02 | 0.02 | 0.02 |
| Net Debt to EBITDA | -4.33 | 0.35 | 1.37 | 2.58 | 4.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.22% | 93.54% | 89.28% | 98.80% | 98.19% |
| Return on Assets (ROA) | -155.13% | -81.27% | -36.57% | -24.24% | -16.72% |
| Return on Equity (ROE) | -262.00% | -98.08% | -39.02% | -25.45% | -17.27% |
| Return on Capital Employed (ROCE) | -275.14% | -104.59% | -43.64% | -25.76% | -17.58% |
| Return on Invested Capital (ROIC) | -21.13% | -103.66% | -43.45% | -25.73% | -17.54% |
| Return on Tangible Assets | -155.13% | -81.27% | -36.57% | -24.24% | -16.72% |
| Earnings Yield | -51.84% | -60.53% | -34.40% | -21.76% | -14.21% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.19 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -1966.95 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 1966.95 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.44 | -1.66 | -1.32 | -1.18 | -0.97 |
| Free Cash Flow Per Share | -1.44 | -1.66 | -1.32 | -1.18 | -0.97 |
| Dividend Paid and CapEx Coverage Ratio | -9141.10 | -1413.86 | -765.80 | -458.54 | -683.37 |
| Capital Expenditure Coverage Ratio | -9141.10 | -1413.86 | -765.80 | -458.54 | -683.37 |
| Operating Cash Flow Coverage Ratio | -0.20 | -73.11 | -61.19 | -241.40 | -51.68 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -47.48% | -51.92% | -30.96% | -19.52% | -12.19% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.93 | -0.00 | -2.91 | -4.60 | -7.04 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.05 | 1.62 | 1.13 | 1.17 | 1.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.11 | -1.93 | -3.23 | -5.12 | -8.20 |
| Price-to-Operating Cash Flow Ratio | -2.11 | -1.93 | -3.23 | -5.13 | -8.22 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.00 | -0.24 | -0.29 | -0.37 |
| Enterprise Value Multiple | -6.26 | -1.30 | -1.56 | -1.97 | -2.84 |
| Enterprise Value | 107.14M | 27.06M | 24.70M | 28.39M | 35.70M |
| EV to EBITDA | -6.26 | -1.30 | -1.56 | -1.97 | -2.84 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.83 | -1.52 | -1.72 | -2.22 | -3.37 |
| EV to Operating Cash Flow | -6.83 | -1.52 | -1.72 | -2.22 | -3.37 |
| Tangible Book Value Per Share | 0.60 | 1.97 | 3.77 | 5.16 | 6.56 |
| Shareholders’ Equity Per Share | 0.60 | 1.97 | 3.77 | 5.16 | 6.56 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.57 | -1.93 | -1.47 | -1.31 | -1.13 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 0.99 | 0.98 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 0.86 | 0.90 | 0.90 | 0.86 |
Currency in USD

